Pancreatic Cancer Research

ResearcherUniversity of IowaActive in the last 2 years

Daniel Berg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9181-8902; OpenAlex author ID A5017215099; NIH RePORTER profile ID 1941879. Sources: ClinicalTrials.gov.

Their work

Papers
4
Trials
1 (principal investigator on 1)
Grants
1
Labs led
0
Collaborators
20
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 1 grant · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 4

  1. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2024.103375↗
  2. Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-1680↗
  3. Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience… Co-author DOI 10.1667/rr14668.1↗
  4. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Co-author DOI 10.1007/s00280-013-2070-8↗

Trials 1

  1. Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer Principal investigator NCT00426127↗

Grants 1

  1. Using Ketogenic Diets to Enhance Radio-Chemo-Therapy Response: A Phase I Trial R21CA161182↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Michael Buatti · 3 shared papers, 1 shared grant, 2012–2024 · strength 0.39
  2. Kellie L. Bodeker · 4 shared papers, 2013–2024 · strength 0.31
  3. Bryan G. Allen · 3 shared papers, 2017–2024 · strength 0.28
  4. Garry R. Buettner · 3 shared papers, 2013–2024 · strength 0.26
  5. Joseph J. Cullen · 3 shared papers, 2013–2024 · strength 0.26
  6. Douglas Robert Spitz · 2 shared papers, 1 shared grant, 2012–2018 · strength 0.22
  7. Naomi H. Fei · 1 shared paper, 2024 · strength 0.16
  8. Chandrikha Chandrasekharan · 1 shared paper, 2024 · strength 0.16
  9. Mandana Kamgar · 1 shared paper, 2024 · strength 0.16
  10. Joseph Michael Caster · 1 shared paper, 2024 · strength 0.16
  11. Juan Du · 2 shared papers, 2013–2018 · strength 0.10
  12. Matthew S. Alexander · 1 shared paper, 2018 · strength 0.07
  13. Brianne R. O’Leary · 1 shared paper, 2018 · strength 0.07
  14. Justin G. Wilkes · 1 shared paper, 2018 · strength 0.07
  15. Amir Zahra · 1 shared paper, 2017 · strength 0.05
  16. Jessemae L. Welsh · 1 shared paper, 2013 · strength 0.03
  17. Mark Levine · 1 shared paper, 2013 · strength 0.03
  18. Thorvardur Ragnar Halfdanarson · 1 shared paper, 2013 · strength 0.03
  19. Jeanne Drisko · 1 shared paper, 2013 · strength 0.03
  20. Nelson S. Yee · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.